Bulk Inquiry
UR 1102
- Epaminurad- Soluble in DMSO
- MF: C14H10Br2N2O3
- MW: 414.05
Description
UR 1102 (Epaminurad) is a inhibitor of the renal urate transporter URAT1 (SLC22A12) inhibitor (Ki = 0.057 µM) with strong selectivity over OAT1 (Ki = 7.2 µM) and OAT3 (Ki = 2.4 µM) in vitro. It effectively increases fractional excretion of urinary uric acid and reduces plasma uric acid more efficiently than Benzbromarone.
Featuring an enhanced pharmacokinetic profile, UR 1102 is a promising therapeutic candidate for gout and hyperuricemia, and an essential tool for URAT1/SLC22A12 mechanistic research.
Key Features
- Potent URAT1 inhibitor with Ki of 0.057 µM
- Selective over OAT1 (Ki =7.2 µM) and OAT3 (Ki = 2.4 µM)
- Modulates URAT1-dependent biological activity (note: URAT1 does not primarily function as a signaling receptor; we can also say transport activity)
- Supports focused URAT1-mediated transport studies in biochemical and cellular systems
Applications
- URAT1 pharmacology and target-validation studies
- URAT1 transport activity studies
- Disease-model research related to hyperuricemia, gout
- Transporter or ion-channel functional assays
More Information
| Parent CAS No. | 1198153-15-9 |
|---|---|
| Chemical Name | (3,5-dibromo-4-hydroxyphenyl)(2H-pyrido[4,3-b][1,4]oxazin-4(3H)-yl)methanone |
| SMILES | C(C1=CC(Br)=C(O)C(Br)=C1)(N1CCOC2C=CN=CC=21)=O |
| MFCD | N.A. |
| InChi | InChI=1S/C14H10Br2N2O3/c15-9-5-8(6-10(16)13(9)19)14(20)18-3-4-21-12-1-2-17-7-11(12)18/h1-2,5-7,19H,3-4H2 |
| InChiKey | ZMVGQIIOXCGAFV-UHFFFAOYSA-N |
| CID | 44608229 |
| Short Description | URAT1 inhibitor |


